Rheumatology Flashcards

1
Q

HLA B27 associations

A

Ankylosing spondylitis
Reactive arthritis
Acute anterior uveitis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

HLA A3 associations

A

Haemochromatosis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

HLA-B51 associations

A

Behcet’s disease

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

HLA-DQ2/DQ8 Associations

A

coeliac disease

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

HLA-DR2 associations

A

narcolepsy

Goodpasture’s

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

HLA-DR3 associations

A
dermatitis herpetiformis
Sjogren's syndrome
primary biliary cirrhosis
Hashimotos
Early onset Myasthenia
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

HLA-DR4 associations

A

type 1 diabetes mellitus*

rheumatoid arthritis - in particular the DRB1 gene (DRB104:01 and DRB104:04 hence the association with DR4)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Anti -Ro

A

SLE–> HB

Sjogrens

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Anti-La

A

Sjogrens

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

anti Jo

A

Polymyositis and dermatomyositis

more common by far in polymyositis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

anti scl-70

A

diffuse cutaneous systemic sclerosis

scleroderma

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

anti centromere

A

limited cutaneous systemic sclerosis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

anti Mi-2

A

most sensitive for dermatomyositis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

anti SMA

A

autoimmune hepatitis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

anti -histone

A

drug induced lupus

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

C-ANCA

A

GPA–>PR3

17
Q

ANA

A

most common in dermatomyositis
100% of drug induced lupus -dsDNA-ve
SLE

18
Q

anti-CCP

A

RA- most specific

19
Q

RF

A

RA most sensitive

Felty's syndrome (around 100%)
Sjogren's syndrome (around 50%)
infective endocarditis (around 50%)
SLE (= 20-30%)
systemic sclerosis (= 30%)
general population (= 5%)
rarely: TB, HBV, EBV, leprosy
20
Q

anti-RNP

A

mixed connective tissue disease

21
Q

pANCA

A

eGPA–> myeloperoxidase

22
Q

anti-smith

A

drug induced lupus

23
Q

Methotrexate MOA

A

antimetabolite that inhibits dihydrofolate reductase, an enzyme essential for the synthesis of purines and pyrimidines.

24
Q

Methotrexate adverse effects

A
mucositis
myelosuppression
pneumonitis
pulmonary fibrosis
liver fibrosis
25
Q

methotrexate monitoring

A

methotrexate is taken weekly, rather than daily
FBC, U&E and LFTs need to be regularly monitored. The Committee on Safety of Medicines recommend ‘FBC and renal and LFTs before starting treatment and repeated weekly until therapy stabilised, thereafter patients should be monitored every 2-3 months’
folic acid 5mg once weekly should be co-prescribed, taken more than 24 hours after methotrexate dose

26
Q

methotrexate interactions

A

avoid prescribing trimethoprim or co-trimoxazole concurrently - increases risk of marrow aplasia
high-dose aspirin increases the risk of methotrexate toxicity secondary to reduced excretion

27
Q

methotrexate toxicity management

A

folinic acid

28
Q

MOA Denosumab

A

monoclonal antibody. It prevents the development of osteoclasts by inhibiting RANKL. Osteoclasts break down bone, and therefore by preventing their development, bone loss is reduced.

29
Q

septic arthritis antibiotic

A

flucloxacillin

clindamycin if penicillin allergic

30
Q

Polyarteritis nodosa features

A

vasculitis affecting medium-sized arteries with necrotizing inflammation leading to aneurysm formation

fever, malaise, arthralgia
weight loss
hypertension
mononeuritis multiplex , sensorimotor polyneuropathy
testicular pain
livedo reticularis
haematuria, renal failure
perinuclear-antineutrophil cytoplasmic antibodies (ANCA) are found in around 20% of patients with ‘classic’ PAN
hepatitis B serology positive in 30% of patients

31
Q

SLE autoantibodies

A

99% are ANA positive
this high sensitivity makes it a useful rule out test, but it has low specificity
20% are rheumatoid factor positive
anti-dsDNA: highly specific (> 99%), but less sensitive (70%)
anti-Smith: highly specific (> 99%), sensitivity (30%)
also: anti-U1 RNP, SS-A (anti-Ro) and SS-B (anti-La)

Anti-Ro antibodies are present in 15% of patients with SLE, but are more frequently associated with Sjörgren’s syndrome.

32
Q

dermatomyositis malignancy

A

(typically ovarian, breast and lung cancer, found in 20-25% - more if patient older). Screening for an underlying malignancy is usually performed following a diagnosis of dermatomyositis

33
Q

antiphospholipid features

A

venous/arterial thrombosis
recurrent fetal loss
livedo reticularis
thrombocytopenia
prolonged APTT (due to an ex-vivo reaction of the lupus anticoagulant autoantibodies with phospholipids involved in the coagulation cascade)
other features: pre-eclampsia, pulmonary hypertension